Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 23, 2019

KCI introduces new Prevena Restor for incision healing

Acelity company KCI has launched the Prevena Restor Bella•Form System for healing and management of post-operative incisions and surrounding soft tissue.

Acelity company KCI has launched the Prevena Restor Bella•Form System for healing and management of post-operative incisions and surrounding soft tissue.

Prevena Restor Bella•Form is intended to stabilise the incision and surrounding surgical area, mitigate oedema and improve healing. It delivers negative pressure to the target area to eliminate exudates.

The system is designed to protect incisions from external contaminants and potentially reduce the risk of surgical site complications.

Furthermore, Bella•Form comes with a therapy time of up to 14 days, increased coverage area and larger dressing to deliver therapy to incision and surrounding soft tissue.

KCI added that the dressing conforms to the patients, with simple application and removal.

The system expands the company’s surgical portfolio, forming part of the Prevena Restor range.

Content from our partners
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

KCI CEO Andrew Eckert said: “With the introduction of the Prevena Restor Bella•Form System, we are advancing how surgeons can care for patients recovering from surgery, such as reconstructive soft tissue procedures. This first-to-market therapy was built specifically with the patient’s recovery journey in mind.

“Prevena Restor Bella•Form System addresses a significant clinical need by reimagining the traditional applications of negative pressure and thinking beyond the incision to help support improved healing in aspirational ways—all backed by the undisputed outcomes of Prevena Therapy.”

KCI focuses on using negative pressure wound therapy for healing, as well as surgical management. Acelity markets the products in more than 90 countries under the KCI brand.

In May, 3M agreed to acquire Acelity and the KCI subsidiaries for approximately $6.72bn. After the completion of the acquisition, KCI will become part of 3M’s Medical Solutions business.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU